U.S. markets close in 5 hours 32 minutes

The Trendlines Group Ltd. (TRNLY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.53000.0000 (0.00%)
As of 3:40PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.5300
Open3.6100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.5300 - 3.5300
52 Week Range2.9900 - 4.2400
Volume3,800
Avg. Volume531
Market Cap58.425M
Beta (5Y Monthly)0.94
PE Ratio (TTM)11.77
EPS (TTM)0.3000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 20, 2019
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • THE TRENDLINES GROUP LTD.
    BGS: Raising target price to $32.00B&G FOODS INC has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • PR Newswire

    Vensica Therapeutics Inks Strategic Partnership with Merz

    Vensica Therapeutics ("Vensica"), a clinical stage biopharmaceutical company, announced that it has signed a strategic collaboration agreement with Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins Vensica has licensed Merz's botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures. Merz has acquired an equity position in Vensica.

  • PR Newswire

    AgroScout Raises $7.5 Million to Expand its AI-based Agronomy Analytics Service

    AgroScout announced today that it has completed a Series A investment round of $7.5 million to expedite the development of its AI cloud platform for remote agronomy, and to increase its accessibility to the 500 million mostly unserved farms worldwide. The platform allows all growers – from the biggest to the smallest – to efficiently comply with the rising demand for sustainable crop protection and carbon accountability. The investment round was led by Kibbutz Yotvata. Other investors include Ag

  • PR Newswire

    First in Human Procedure with Vessi Medical's Cryotherapy System for Bladder Cancer

    Vessi Medical ("Vessi"), announced that it successfully completed a first-in-human case with its minimally invasive cryoablation solution for superficial bladder cancer (NMIBC). The procedure was performed at Rambam Healthcare Campus in Haifa, Israel.